CTLA4 and neoplasm: The most prominent examples of this are the checkpoint inhibitors that target the inhibitory receptors PD‐1 and CTLA‐4 on T cells, preventing the tumour‐initiated deactivation of cytotoxic T lymphocytes in the local microenvironment leading to a better antitumour immune response and better treatment outcomes (Abdou et al., 2020).